Composite synthetic peptide construct eliciting neutralizing antibodies and cytotoxic t lymphocytes against hiv
Abstract
[Subject] Offer of the peptide which induces T helper response, a cytotoxic lymphocyte response, and a counteractive antibody in two or more hosts. [Solution means] The peptide structure containing the multiplex determinant site T helper peptide originating in the envelope protein of HIV, It is the polypeptide possessing the peptide 18 in V3 loop of HIV*1 and gp160 it is indicated to be that correspond to the main counteractive determinant site of HIV-IIIB, and a superior CTL epitope is included, Each response arises in two or more individuals of a mammals kind which present an extensive transplantation antigen haplotype. [Selection figure] Nothing
Term
No projected expiry on record.
- Priority
- Filed
- Granted
- Today
95 members in 12 offices
Priority claims1
| Document | Office | Kind | Date |
|---|---|---|---|
| 6098893 | United States of America | A |
Members95
| Document | Office | Kind | |
|---|---|---|---|
| US4621006A | United States of America | A | |
| IL84980D0 | Israel | D0 | |
| EP0273716A2 | European Patent Office (EPO) | A2 | |
| WO8805051A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU1365788A | Australia | A | |
| JPS63503227A | Japan | A | |
| US4853065A | United States of America | A | |
| WO8907112A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU3204489A | Australia | A | |
| EP0273716A3 | European Patent Office (EPO) | A3 | |
| AU592258B2 | Australia | B2 | |
| WO9000901A1 | World Intellectual Property Organization (WIPO) | A1 | |
| IL91007D0 | Israel | D0 | |
| AU3967089A | Australia | A | |
| EP0400076A1 | European Patent Office (EPO) | A1 | |
| US5021282A | United States of America | A | |
| EP0429477A1 | European Patent Office (EPO) | A1 | |
| US5030449A | United States of America | A | |
| JPH03503166A | Japan | A | |
| JPH03504384A | Japan | A | |
| EP0400076A4 | European Patent Office (EPO) | A4 | |
| EP0429477A4 | European Patent Office (EPO) | A4 | |
| US5081226A | United States of America | A | |
| AU621097B2 | Australia | B2 | |
| AU624628B2 | Australia | B2 | |
| US5154963A | United States of America | A | |
| CA2114849A1 | Canada | A1 | |
| WO9304697A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO9305812A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2569392A | Australia | A | |
| AU2571992A | Australia | A | |
| IL84980A | Israel | A | |
| IL89012A | Israel | A | |
| EP0273716B1 | European Patent Office (EPO) | B1 | |
| AT92934T | Austria | T | |
| CA2131153A1 | Canada | A1 | |
| DE3787002D1 | Germany | D1 | |
| WO9318055A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU3787893A | Australia | A | |
| DE3787002T2 | Germany | T2 | |
| WO9318055A3 | World Intellectual Property Organization (WIPO) | A3 | |
| EP0601108A1 | European Patent Office (EPO) | A1 | |
| CA2162880A1 | Canada | A1 | |
| WO9426785A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU7017394A | Australia | A | |
| EP0630385A1 | European Patent Office (EPO) | A1 | |
| JPH07501516A | Japan | A | |
| JPH0762031B2 | Japan | B2 | |
| IL91007A | Israel | A | |
| AU665023B2 | Australia | B2 | |
| US5500269A | United States of America | A | |
| EP0701572A1 | European Patent Office (EPO) | A1 | |
| EP0400076B1 | European Patent Office (EPO) | B1 | |
| AU668927B2 | Australia | B2 | |
| AT138077T | Austria | T | |
| DE68926499D1 | Germany | D1 | |
| EP0429477B1 | European Patent Office (EPO) | B1 | |
| AT144143T | Austria | T | |
| DE68927348D1 | Germany | D1 | |
| DE68926499T2 | Germany | T2 | |
| JP2569185B2 | Japan | B2 | |
| JPH09500614A | Japan | A | |
| DE68927348T2 | Germany | T2 | |
| EP0601108A4 | European Patent Office (EPO) | A4 | |
| CA1339240C | Canada | C | |
| JP2676166B2 | Japan | B2 | |
| US5711947A | United States of America | A | |
| AU688333B2 | Australia | B2 | |
| US5820865A | United States of America | A | |
| US5932218A | United States of America | A | |
| EP0701572B1 | European Patent Office (EPO) | B1 | |
| AT183200TThis record | Austria | T | |
| US5939074A | United States of America | A | |
| DE69420034D1 | Germany | D1 | |
| EP0601108B1 | European Patent Office (EPO) | B1 | |
| AT185275T | Austria | T | |
| US5976541A | United States of America | A | |
| DE69230106D1 | Germany | D1 | |
| ES2138086T3 | Spain | T3 | |
| CA1340896C | Canada | C | |
| CA1340907C | Canada | C | |
| GR3031790T3 | Greece | T3 | |
| DE69420034T2 | Germany | T2 | |
| DK0701572T3 | Denmark | T3 | |
| DE69230106T2 | Germany | T2 | |
| DK0601108T3 | Denmark | T3 | |
| US6214347B1 | United States of America | B1 | |
| US6294322B1 | United States of America | B1 | |
| CA2162880C | Canada | C | |
| JP2006056893A | Japan | A | |
| JP3802049B2 | Japan | B2 | |
| ES2257733T3 | Spain | T3 | |
| US7094405B1 | United States of America | B1 | |
| CA2114849C | Canada | C | |
| CA2131153C | Canada | C |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Publication of translation of european patent specificationUEP | UEP |
Numbers
- Application
- 94919119
Titles2
- German
- SYNTHETISCHE MISCHPEPTIDE, DIE DIE ENTSTEHUNG VON NEUTRALISIERENDEN ANTIKÖRPERN UND DIE WIRKUNG DER CYTOTOXISCHEN T-LYMPHOZYTEN GEGEN HIV HERVORUFEN
- English
- SYNTHETIC MIXED PEPTIDES THAT CAUSE THE GENERATION OF NEUTRALIZING ANTIBODIES AND THE EFFECT OF THE CYTOTOXIC T-LYMPHOCYTES AGAINST HIV
Classification
- CPC, 20
- C07K14/005
- A61K38/03
- A61K38/55
- A61K38/556
- A61K39/00
- A61K39/12
- A61K39/21
- A61K2039/545
- A61K2039/55516
- A61K2039/55566
- A61K2039/55577
- A61K2039/57
- A61K2039/645
- A61P31/12
- A61P31/18
- A61P37/02
- C07K2319/00
- C12N2740/16122
- C12N2740/16134
- Y02A50/30
- IPC, 10
- A61K38 00
- A61K38 03
- A61K38 55
- A61K39 00
- A61P31 12
- A61P31 18
- A61P37 02
- C07K14 155
- C07K14 16
- C07K19 00